Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in Subjects With Rheumatoid Arthritis (RA)
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-05-23
- Last Posted Date
- 2009-03-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 216
- Registration Number
- NCT00111423
Treatment for Patients With Non-Myeloid Malignancies Receiving Chemotherapy
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-05-18
- Last Posted Date
- 2008-02-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 718
- Registration Number
- NCT00111137
Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD)
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-05-17
- Last Posted Date
- 2010-04-23
- Lead Sponsor
- Amgen
- Target Recruit Count
- 850
- Registration Number
- NCT00110929
Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-03-04
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 111
- Registration Number
- NCT00104650
A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic Syndrome
Phase 2
Completed
- Conditions
- First Posted Date
- 2004-11-03
- Last Posted Date
- 2010-01-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 209
- Registration Number
- NCT00095264
Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-10-20
- Last Posted Date
- 2013-05-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 400
- Registration Number
- NCT00094484
Preference of Rheumatoid Arthritis (RA) Patients of Enbrel® (Etanercept) Auto-Injector Versus Enbrel® Pre-Filled Syringes
Phase 4
Completed
- Conditions
- First Posted Date
- 2004-10-18
- Last Posted Date
- 2008-12-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 215
- Registration Number
- NCT00094341
Study to Assess Darbepoetin Alfa in Subjects With Chronic Kidney Disease
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-10-11
- Last Posted Date
- 2013-05-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1100
- Registration Number
- NCT00093977
Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2004-10-08
- Last Posted Date
- 2013-05-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 71
- Registration Number
- NCT00093873
Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer
- First Posted Date
- 2004-09-21
- Last Posted Date
- 2013-05-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1000
- Registration Number
- NCT00091858
© Copyright 2024. All Rights Reserved by MedPath